Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vaxcyte
Biotech
Vaxcyte’s pneumococcal shot holds its own against Pfizer, Merck
Vaxcyte saw its stock jump after the biotech’s 31-valent pneumococcal vaccine went head-to-head with Prevnar 20 and Capvaxive in a phase 3 test.
James Waldron
Oct 5, 2026 8:41am
Longtime Takeda R&D chief to depart next June—Chutes & Ladders
Sep 11, 2026 8:30am
Recursion refreshes leadership with CEO swap—Chutes & Ladders
Nov 7, 2025 8:30am
Vaxcyte surges on 'stunning' 31-valent PCV win against Pfizer
Sep 3, 2024 10:32am
BioMarin CEO replaces commercial chief—Chutes & Ladders
Jan 19, 2024 8:30am
Pivotal bioVenture Partners unveils $389M fund
Dec 18, 2023 7:00am
